Andrew Cooper
Stock Analyst at Raymond James
(2.24)
# 2,788
Out of 5,239 analysts
130
Total ratings
40.52%
Success rate
-1.78%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $17.53 | +156.70% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $84.98 | +11.79% | 4 | Oct 24, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $8.17 | +95.84% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $54.01 | +44.42% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $99.94 | -38.96% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $99.30 | +15.81% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $459.30 | +16.48% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $4.07 | +145.70% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $15.80 | +58.23% | 2 | May 5, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $220.59 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $166.26 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.40 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $204.21 | -58.38% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $11.12 | +583.45% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.04 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.75 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $39.56 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.98 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $17.53
Upside: +156.70%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $84.98
Upside: +11.79%
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $8.17
Upside: +95.84%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $54.01
Upside: +44.42%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $99.94
Upside: -38.96%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $99.30
Upside: +15.81%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $459.30
Upside: +16.48%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $4.07
Upside: +145.70%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $15.80
Upside: +58.23%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $220.59
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $166.26
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $21.40
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $204.21
Upside: -58.38%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $11.12
Upside: +583.45%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.04
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.75
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $39.56
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.98
Upside: -